Drug Trial Radar · NCT07625618
A Pharmacokinetic and Safety Study of MY008211A Tablets in Subjects With Impaired or Normal Hepatic Function
Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Sep 20, 2024
Primary completion
Dec 28, 2024
Study completion Dec 28, 2024
Sponsor
- Lead sponsor
- Wuhan Createrna Science and Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single-center, non-randomized, open-label, parallel, single-dose study to evaluate the PK profile and safety of MY008211A Tablets in subjects with hepatic impairment.
Conditions
- Hepatic Insufficiency (MeSH ID: D048550)
Interventions
MY008211A tabletsDrug
Each subject will take a single oral dose of 400 mg MY008211A Tablets under fasting conditions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: up to 12 weeks
- AUC0-lastTime frame: up to 12 weeks
- AUC0-infTime frame: up to 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Hospital of Jilin University
Jilin City, Changchun, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.